Analytical Data
-
Gene name
PRSS56
- Application
-
Species
Human
-
Source
E. coli
-
Tag
N- His & C- Myc
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P0CW18
-
Expression Region
20-603aa
-
Molecular Weight
70.0 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
PRSS56, a member of the serine protease family, has gained significant attention in recent years due to its diverse biological functions and implications in various diseases. Initially identified as a gene associated with high myopia, further research has revealed its role in ocular development and the regulation of extracellular matrix composition in the eye. PRSS56 is expressed in several tissues, including the retina and ciliary body, suggesting its involvement in the development and maintenance of ocular structures. Beyond ophthalmology, PRSS56 has been implicated in other physiological processes, such as neurodevelopment and the modulation of inflammatory responses. Studies show that mutations in the PRSS56 gene can lead to developmental anomalies and contribute to conditions like glaucoma and other ocular disorders. The recombinant protein form of PRSS56 is particularly valuable for in vitro studies, enabling researchers to elucidate its enzymatic activity and molecular interactions. This knowledge could pave the way for novel therapeutic strategies targeting PRSS56 in myopia and other diseases. Additionally, understanding how PRSS56 regulates proteolytic pathways and cellular signaling may reveal broader implications in developmental biology and pathology. Overall, the investigation of PRSS56 as a recombinant protein presents a promising avenue for advancing our understanding of its functions and therapeutic potential.
